{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.8","value":"88.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"532"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"93.0","value":"146"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"519"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"88.1","value":"149"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"502"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"96.3","value":"242"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"111","value":"286"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"}],"units":"Participants"}],"title":"Cycle 16 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"532"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG000","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"MEAN","populationDescription":"PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Cycle 2 Day 1 predose, Cycle 3 Day 1 Predose, Cycle 4 Day 1 predose, Cycle 8 Day 1 predose, Cycle 16 Day 1 predose","title":"Minimum Serum Concentration (Cmin) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"µg/mL"}